US · Healthcare · Drug Manufacturers - General
EPS came in at 2.63 against a street estimate of 2.50 — a beat of 5.2%.
Analysts rate AstraZeneca PLC a buy (10 buy, 1 hold, 1 sell out of 12) with an average price target of $207.16.
| Fund | Stake |
|---|---|
| Investors Finance Co PLC | 3.33% |
| Vanguard Capital Management, LLC | 2.93% |
| Capital Research & Mgmt Co - Division 3 | 2.23% |
| NORGES BANK | 2.18% |
| Capital World Investors | 1.94% |
| FMR Inc | 1.86% |
| Wellington Management Company LLP | 1.84% |
| Legal & General Group PLC | 1.66% |
| Document | Date |
|---|---|
| Astrazeneca completes equity investment in summit (6-K) · Q4 2026 HEADLINE NUMBERS • AstraZeneca completed a $2 billion equity investment in Summit Therapeutics on 5 October 2026. • The investment is intended to a | 2026-10-05 |
| Az & ds collaboration with summit for datroway (6-K) · Q4 2026 HEADLINE NUMBERS • On 02 October 2026, AstraZeneca and Daiichi Sankyo announced a clinical collaboration with Summit Therapeutics to evaluate Datrowa | 2026-10-02 |
| Admission of further securities to trading (6-K) · Q4 2026 HEADLINE NUMBERS • AstraZeneca issued and admitted 9,828 ordinary shares to trading. • Following admission, total shares outstanding increased to 1, | 2026-10-01 |
| Astrazeneca announces equity investment in summit (6-K) · Q3 2026 HEADLINE NUMBERS • AstraZeneca agreed to invest $2 billion in newly issued Summit Therapeutics equity. • The investment will give AstraZeneca rights | 2026-09-29 |
| Trixeo approved in eu for asthma (6-K) · Q3 2026 HEADLINE NUMBERS • AstraZeneca received European Commission approval on 23 September 2026 for Trixeo Aerosphere as a maintenance treatment for asthma | 2026-09-23 |
| Klygefa recommended for eu approval by chmp (6-K) · Q3 2026 HEADLINE NUMBERS • AstraZeneca’s Klygefa (gefurulimab) received a positive recommendation from the European Medicines Agency’s CHMP on 21 September 2 | 2026-09-21 |
| Enhertu recommended for approval in eu in early bc (6-K) · Q3 2026 HEADLINE NUMBERS • The European Medicines Agency’s CHMP recommended Enhertu for approval in the EU as an adjuvant treatment for adults with HER2-posi | 2026-09-21 |
| Update on serena-4 phase iii trial (6-K) · Q3 2026 HEADLINE NUMBERS • AstraZeneca reported that the SERENA-4 Phase III trial did not meet its primary objective of a statistically significant improveme | 2026-09-14 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $1.06 / share ex-date Aug 7, 2026 · pay Sep 8, 2026 | 2026-08-07 |
| Dividend | $2.17 / share ex-date Feb 20, 2026 · pay Mar 23, 2026 | 2026-02-20 |
| Split | 1 : 2 effective Feb 2, 2026 | 2026-02-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AstraZeneca PLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.